Comparative Efficacies of Candidate Antibiotics against Yersinia pestis in an In Vitro Pharmacodynamic Model
Authors:
Open Access
- 1 June 2011
- journal article
- research article
- Published by American Society for Microbiology in Antimicrobial Agents and Chemotherapy
- Vol. 55 (6) , 2623-2628
Abstract
Yersinia pestis, the bacterium that causes plague, is a potential agent of bioterrorism. Streptomycin is the “gold standard” for the treatment of plague infections in humans, but the drug is not available in many countries, and resistance to this antibiotic occurs naturally and has been generated in the laboratory. Other antibiotics have been shown to be active against Y. pestis in vitro and in vivo. However, the relative efficacies of clinically prescribed regimens of these antibiotics with streptomycin and with each other for the killing of Yersinia pestis are unknown. The efficacies of simulated pharmacokinetic profiles for human 10-day clinical regimens of ampicillin, meropenem, moxifloxacin, ciprofloxacin, and gentamicin were compared with the gold standard, streptomycin, for killing of Yersinia pestis in an in vitro pharmacodynamic model. Resistance amplification with therapy was also assessed. Streptomycin killed the microbe in one trial but failed due to resistance amplification in the second trial. In two trials, the other antibiotics consistently reduced the bacterial densities within the pharmacodynamic systems from 108 CFU/ml to undetectable levels (2 CFU/ml) between 1 and 3 days of treatment. None of the comparator agents selected for resistance. The comparator antibiotics were superior to streptomycin against Y. pestis and deserve further evaluation.Keywords
This publication has 22 references indexed in Scilit:
- Plague into the 21st CenturyClinical Infectious Diseases, 2009
- Use of an In Vitro Pharmacodynamic Model To Derive a Linezolid Regimen That Optimizes Bacterial Kill and Prevents Emergence of Resistance in Bacillus anthracisAntimicrobial Agents and Chemotherapy, 2008
- Comparison of 2 Antibiotics That Inhibit Protein Synthesis for the Treatment of Infection withYersinia pestisDelivered by Aerosol in a Mouse Model of Pneumonic PlagueThe Journal of Infectious Diseases, 2007
- Impact of Resistance Selection and Mutant Growth Fitness on the Relative Efficacies of Streptomycin and Levofloxacin for Plague TherapyAntimicrobial Agents and Chemotherapy, 2007
- Effective Antimicrobial Regimens for Use in Humans for Therapy ofBacillus anthracisInfections and Postexposure ProphylaxisAntimicrobial Agents and Chemotherapy, 2005
- Efficacy of the latest fluoroquinolones against experimental Yersinia pestisInternational Journal of Antimicrobial Agents, 2004
- A Case of Plague Successfully Treated with Ciprofloxacin and Sympathetic Blockade for Treatment of GangreneClinical Infectious Diseases, 2003
- Multidrug Resistance inYersinia pestisMediated by a Transferable PlasmidNew England Journal of Medicine, 1997
- Yersinia pestis Infection in Vietnam. II; Quantitative Blood Cultures and Detection of Endotoxin in the Cerebrospinal Fluid of Patients with MeningitisThe Journal of Infectious Diseases, 1976
- The Chemotherapy of Experimental Plague in the Primate HostThe Journal of Infectious Diseases, 1953